See more : ifa systems AG (FYSSY) Income Statement Analysis – Financial Results
Complete financial analysis of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (RGEDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- BioGend Therapeutics Co., Ltd. (6733.TWO) Income Statement Analysis – Financial Results
- Mitsubishi Steel Mfg. Co., Ltd. (5632.T) Income Statement Analysis – Financial Results
- Enterprise Group, Inc. (ETOLF) Income Statement Analysis – Financial Results
- Rasna Therapeutics, Inc. (RASP) Income Statement Analysis – Financial Results
- Sanrio Company, Ltd. (SNROF) Income Statement Analysis – Financial Results
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (RGEDF)
About Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products worldwide. The company operates through two segments, Pharmaceuticals, and Wholesale and Retail. It develops and manufactures products in various therapeutic areas, including women's healthcare, cardiovascular, and central nervous system. The company women's healthcare products include contraceptives, endometriosis, fertility, menopause, vaginal infections, and preparations used for the treatment of uterine fibroids. It also offers central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, the company produces various over-the-counter products for various health problems comprising Escapelle and Postinor, an emergency contraceptive pill; Panangin and Folik for pregnancy supplementation; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Groprinosin for antiviral and immunostimulant; Moilec for back and joint pain; Fasconal, a pain relief tablet; Magnezin, a magnesium supplementation; Aflamil, an anti-inflammatory and antirheumatic cream; Oralsept, a sore throat, anti-inflammatory, local anesthetic, and before and after oral surgery spray; Lordestin for allergy; and Curiosin for wound care. Further, it provides financial and accounting, social welfare, portfolio and project management, catering, carriage transportation, engineering, quality control, trading, asset management, and biotechnological services. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. was founded in 1901 and is headquartered in Budapest, Hungary.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 805.16B | 802.76B | 630.60B | 566.78B | 507.79B | 445.48B | 444.36B | 389.69B | 365.22B | 353.71B | 351.89B | 326.70B | 307.87B | 275.31B | 267.34B | 236.52B | 224.08B | 208.62B | 171.72B | 148.76B |
| Cost of Revenue | 283.83B | 342.29B | 281.32B | 248.01B | 230.02B | 191.65B | 191.28B | 164.85B | 144.61B | 139.65B | 132.15B | 125.00B | 114.53B | 107.14B | 116.44B | 108.42B | 104.38B | 89.70B | 75.57B | 71.10B |
| Gross Profit | 521.32B | 460.46B | 349.27B | 318.77B | 277.78B | 253.84B | 253.08B | 224.84B | 220.61B | 214.06B | 219.74B | 201.70B | 193.34B | 168.18B | 150.90B | 128.10B | 119.70B | 118.92B | 96.15B | 77.66B |
| Gross Profit Ratio | 64.75% | 57.36% | 55.39% | 56.24% | 54.70% | 56.98% | 56.95% | 57.70% | 60.40% | 60.52% | 62.45% | 61.74% | 62.80% | 61.09% | 56.44% | 54.16% | 53.42% | 57.00% | 55.99% | 52.21% |
| Research & Development | 78.34B | 75.11B | 61.01B | 53.98B | 48.86B | 40.63B | 39.99B | 35.24B | 34.91B | 43.75B | 40.80B | 38.85B | 28.71B | 27.13B | 23.57B | 18.40B | 18.06B | 14.49B | 12.62B | 10.61B |
| General & Administrative | 50.57B | 34.86B | 28.67B | 28.21B | 28.98B | 24.07B | 23.37B | 20.34B | 19.40B | 19.59B | 19.32B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 146.05B | 147.49B | 114.60B | 105.56B | 116.30B | 115.58B | 114.88B | 107.56B | 98.31B | 101.72B | 107.00B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 196.62B | 182.35B | 143.26B | 129.45B | 145.28B | 135.27B | 138.26B | 127.90B | 117.71B | 121.32B | 126.32B | 112.98B | 103.53B | 81.43B | 70.98B | 67.89B | 58.21B | 53.05B | 43.68B | 31.66B |
| Other Expenses | 57.00B | 49.45B | 9.18B | 15.94B | -3.93B | 0.00 | 54.12B | 7.08B | 1.31B | 11.25B | 6.18B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.61B | 1.13B | 0.00 |
| Operating Expenses | 331.96B | 306.91B | 213.44B | 203.68B | 237.88B | 180.28B | 232.37B | 170.22B | 153.93B | 176.31B | 173.30B | 151.82B | 132.24B | 108.56B | 94.55B | 86.29B | 76.27B | 70.14B | 57.43B | 42.27B |
| Cost & Expenses | 615.79B | 649.20B | 494.76B | 440.00B | 427.04B | 371.93B | 423.65B | 335.07B | 298.54B | 315.96B | 305.44B | 276.82B | 246.77B | 215.70B | 210.99B | 194.71B | 180.65B | 159.85B | 133.01B | 113.37B |
| Interest Income | 24.84B | 13.42B | 2.95B | 915.00M | 914.00M | 1.35B | 1.56B | 2.57B | 2.64B | 3.22B | 4.07B | 4.65B | 3.42B | 4.23B | 4.86B | 3.15B | 2.80B | 2.44B | 2.71B | 3.51B |
| Interest Expense | 15.34B | 8.03B | 663.00M | 643.00M | 729.00M | 2.00M | 990.00M | 827.00M | 1.16B | 1.37B | 1.56B | 1.81B | 1.27B | 169.00M | 583.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 45.57B | 42.93B | 40.29B | 35.66B | 35.63B | 34.82B | 34.66B | 32.81B | 31.16B | 29.28B | 28.30B | 26.88B | 24.46B | 21.14B | 19.72B | 20.58B | 20.21B | 18.75B | 16.59B | 12.96B |
| EBITDA | 262.59B | 233.58B | 175.64B | 159.36B | 90.24B | 100.51B | 48.11B | 85.52B | 90.78B | 69.22B | 77.19B | 78.24B | 79.63B | 89.03B | 77.15B | 63.13B | 55.26B | 70.86B | 62.77B | 52.90B |
| EBITDA Ratio | 32.61% | 29.10% | 27.85% | 28.12% | 21.29% | 22.56% | 10.83% | 21.94% | 24.86% | 19.57% | 21.94% | 23.95% | 25.86% | 32.34% | 28.86% | 26.69% | 24.66% | 33.97% | 36.56% | 35.56% |
| Operating Income | 189.36B | 153.56B | 135.83B | 126.77B | 80.76B | 73.55B | 20.71B | 54.62B | 66.68B | 37.75B | 46.45B | 49.88B | 61.10B | 59.62B | 56.35B | 41.81B | 43.43B | 48.77B | 38.71B | 35.39B |
| Operating Income Ratio | 23.52% | 19.13% | 21.54% | 22.37% | 15.90% | 16.51% | 4.66% | 14.02% | 18.26% | 10.67% | 13.20% | 15.27% | 19.85% | 21.65% | 21.08% | 17.68% | 19.38% | 23.38% | 22.54% | 23.79% |
| Total Other Income/Expenses | -17.82B | -8.95B | 6.80B | -12.51B | -30.57B | -29.60B | -6.81B | 11.41B | -6.81B | -11.95B | -2.81B | -326.00M | -7.19B | 8.11B | 497.00M | 741.00M | -8.38B | 3.34B | 7.47B | 4.55B |
| Income Before Tax | 171.54B | 165.66B | 143.47B | 114.26B | 50.19B | 43.95B | 13.90B | 66.43B | 59.88B | 25.80B | 43.64B | 49.55B | 53.91B | 67.73B | 56.85B | 42.55B | 35.05B | 52.11B | 46.19B | 39.94B |
| Income Before Tax Ratio | 21.31% | 20.64% | 22.75% | 20.16% | 9.88% | 9.87% | 3.13% | 17.05% | 16.39% | 7.29% | 12.40% | 15.17% | 17.51% | 24.60% | 21.26% | 17.99% | 15.64% | 24.98% | 26.90% | 26.85% |
| Income Tax Expense | 10.89B | -5.09B | 5.40B | 9.11B | 2.42B | 7.76B | 3.83B | 1.20B | 6.01B | 761.00M | 1.21B | 841.00M | 218.00M | 3.14B | 5.95B | 1.88B | 1.81B | 711.00M | 543.00M | -107.00M |
| Net Income | 158.85B | 169.08B | 139.63B | 104.68B | 47.14B | 35.35B | 8.89B | 66.20B | 53.86B | 24.95B | 42.77B | 49.24B | 49.28B | 64.48B | 50.99B | 41.41B | 33.34B | 51.28B | 45.31B | 39.85B |
| Net Income Ratio | 19.73% | 21.06% | 22.14% | 18.47% | 9.28% | 7.93% | 2.00% | 16.99% | 14.75% | 7.05% | 12.15% | 15.07% | 16.01% | 23.42% | 19.07% | 17.51% | 14.88% | 24.58% | 26.39% | 26.79% |
| EPS | 859.72 | 907.39 | 750.65 | 562.90 | 253.40 | 189.72 | 47.71 | 356.21 | 290.70 | 134.86 | 229.94 | 265.85 | 264.94 | 346.36 | 273.99 | 222.74 | 179.17 | 275.35 | 243.55 | 214.17 |
| EPS Diluted | 859.72 | 907.39 | 750.65 | 562.90 | 253.40 | 189.72 | 47.71 | 356.21 | 290.70 | 134.86 | 229.46 | 264.20 | 264.43 | 345.97 | 273.57 | 222.19 | 178.87 | 275.14 | 243.13 | 213.80 |
| Weighted Avg Shares Out | 184.77M | 186.33M | 186.01M | 185.97M | 186.01M | 186.31M | 186.22M | 185.85M | 185.29M | 185.01M | 185.99M | 185.22M | 186.01M | 186.16M | 186.09M | 185.91M | 186.06M | 186.23M | 186.05M | 186.04M |
| Weighted Avg Shares Out (Dil) | 184.77M | 186.33M | 186.01M | 185.97M | 186.01M | 186.31M | 186.22M | 185.85M | 185.29M | 185.01M | 186.38M | 186.38M | 186.37M | 186.37M | 186.37M | 186.37M | 186.37M | 186.37M | 186.37M | 186.37M |
Source: https://incomestatements.info
Category: Stock Reports